BCL2A1 and astrocytoma (excluding glioblastoma): studied 54 patients with WHO grade II astrocytomas by quantitative RT‐PCR and immunohistochemical assay,101 and the authors found that patients with astrocytomas and oligoastrocytomas showed high BCL2A1 expression, which was also associated with poor seizure control.